腹部实体器官移植中的多重耐药肠杆菌目感染
本综述检索肾移植和肝移植人群中多重耐药革兰阴性杆菌感染的研究,包括随机对照与观察性研究。综述指出,实体器官移植受者多重耐药感染负担持续增加且与显著死亡率相关,缺乏早期适当抗菌治疗可能导致高死亡率,尤其在产金属β-内酰胺酶的情况下;识别定植/多重耐药菌高危患者对评估限制继发感染风险和减少广谱抗菌药物不适当使用的策略似乎很重要。
要点
- 实体器官移植受者多重耐药革兰阴性杆菌感染与高发病率和高死亡率相关。
- 缺乏早期适当抗菌治疗可能导致移植受者多重耐药感染高死亡率,尤其产金属β-内酰胺酶时。
- 作者认为识别多重耐药菌定植高危患者对评估限制继发感染和减少广谱抗菌药物不适当使用的策略似乎重要。
核心结论
- 多重耐药革兰阴性杆菌与实体器官移植受者的高发病率和高死亡率相关。
- 作者认为识别多重耐药菌定植高危患者以评估限制继发感染风险和减少广谱抗菌药物不适当使用的策略似乎很重要。
研究设计与样本
- 综述检索肾移植和肝移植患者人群中多重耐药革兰阴性杆菌感染的研究,纳入随机对照研究和观察性研究。
主要发现
- 实体器官移植是终末期器官疾病患者的最佳治疗选择。
- 随着预防改善,机会性感染发生率下降,而多重耐药细菌尤其是革兰阴性菌相关的「经典」感染负担持续增加。
- 近二十年来,多种多重耐药病原体已成为该特定人群感染的相关原因,并伴有显著死亡率。
- 与移植供体候选者和受者管理相关的若干因素增加移植受者多重耐药感染风险。
- 移植受者对多重耐药感染的高度易感性挑战经验性治疗的选择,而其适当性只能事后验证。
关键数值与推荐
- 移植受者对多重耐药感染高度易感,经验性治疗的适当性只能事后验证。
临床怎么用
- 作者认为识别多重耐药菌定植高危患者似乎很重要,以评估限制继发感染风险和减少广谱抗菌药物不适当使用的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplant recipients are highly susceptible to multidrug-resistant (MDR) related infections. The lack of early appropriate antimicrobial treatment may contribute to the high mortality due to MDR-related infections in transplant recipients especially in case of metallo-β-lactamases. OBJECTIVES: In this review, we present the current state of knowledge concerning multidrug-resistant Gram negative bacilli's risk management in the care of solid-organ transplant recipients and suggest control strategies. SOURCES: We searched for studies treating MDR g-negative bacilli related infections in the renal and hepatic transplant patient population. We included randomized and observational studies. CONTENT: Solid-organ transplant is the best therapeutic option for patients diagnosed with end-stage organ disease. While the incidence of opportunistic infections is decreasing due to better prevention, the burden of "classical" infections related to MDR bacteria especially related to Gram-negative bacteria is constantly increasing. Over the last two decades, various MDR pathogens have emerged as a relevant cause of infection in this specific population associated with significant mortality. Several factors related to the management of transplant donor candidates and recipients increase the risk of MDR infections in transplant recipients. The awareness of this high susceptibility of transplant recipients to MDR-related infections challenges the choice of empirical therapy, while its appropriateness can only be validated a posteriori. Indeed, the lack of early appropriate antimicrobial treatment may contribute to the high mortality due to MDR-related infections in transplant recipients especially in case of metallo-β-lactamases. IMPLICATIONS: Multidrug-resistant Gram-negative bacteria are associated with high morbidity and mortality in solid organ transplant recipients. It seems important to identify patients at risk of colonization/MDR bacteria to evaluate strategies to limit the risk of secondary infections and to minimize the inappropriate use of broad-spectrum antibiotics.
引用
- Pilmis B, Weiss E, Scemla A, et al. Multidrug-resistant Enterobacterales infections in abdominal solid organ transplantation. Clin Microbiol Infect. 2022. PMID: 35716912. doi:10.1016/j.cmi.2022.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。